Aclaris Therapeutics, INC. (ACRS) — 8-K Filings

8-K Filings (10)

• Aclaris Therapeutics Files 8-K — Oct 14, 2025 Risk: low
  Aclaris Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing does not
• Aclaris Therapeutics Files 8-K — Jul 29, 2025 Risk: low
  On July 29, 2025, Aclaris Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements
• Aclaris Therapeutics Files 8-K — Jun 30, 2025 Risk: low
  Aclaris Therapeutics, Inc. filed an 8-K on June 30, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing do
• Aclaris Therapeutics Files 8-K with Corporate Governance Updates — Jun 5, 2025 Risk: medium
  Aclaris Therapeutics, Inc. filed an 8-K on June 5, 2025, reporting on several key events. These include the departure of directors or certain officers, the elec
• Aclaris Therapeutics Files 8-K — Jan 13, 2025 Risk: low
  Aclaris Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on Regulation FD disclosures and financial statements. The filing does not contain specif
• Aclaris Therapeutics Files 8-K on Agreements & Officer Changes — Nov 18, 2024 Risk: medium
  Aclaris Therapeutics, Inc. filed an 8-K on November 18, 2024, reporting on several key events. These include entering into a material definitive agreement, unre
• Aclaris Therapeutics Files 8-K — Jul 16, 2024 Risk: medium
  On July 16, 2024, Aclaris Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Financial State
• Aclaris Therapeutics Files 8-K on Shareholder Vote — Jun 7, 2024 Risk: low
  Aclaris Therapeutics, Inc. filed an 8-K on June 7, 2024, reporting on a matter submitted to a vote of its security holders on June 6, 2024. The filing details t
• Aclaris Therapeutics Announces Board and Executive Changes — Mar 19, 2024 Risk: low
  Aclaris Therapeutics, Inc. announced on March 14, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Karen L. Smith was appoi
• Aclaris Therapeutics Files 8-K on Operations, Officer Changes — Jan 19, 2024
  Aclaris Therapeutics, Inc. filed an 8-K on January 19, 2024, reporting events that occurred on January 15, 2024. This filing indicates that the company is repor

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX